xxxxEN.qxd

Similar documents
untitled

Microsoft PowerPoint - LCテクノ ポスター 塚本

SEC (SEC) SEC SEC SEC 2


untitled

バイアル新規ユーザー様限定 ガラス製容器 -Si-O H シラノール -Si-O H -Si O -Si イオン的吸着 疎水的吸着シロキサン logp pka + N 塩基性化合物 疎水的吸着 水溶液 P P 製容器, 7,7

Agilent Infinity ELSD ELSD ( ) ( ºC ) W x D x H mm LED ELSD ELSD ELSD UV UV LC/MS RSD % Column: Agilent Pursuit C8, x.6 mm, µm Eluent: Water: Acetonit

COSMOSIL.indd

untitled

JP.qxd

2 (FDA) 1 1 A D E K 1 LC UV 15 HPLC 3.5 UHPLC Agilent 12 Infinity LC Agilent 12 Infinity (G1311B) Agilent 12 Infinity (G13E) Agilent 12 Infinity (G131

HPLC カラム 総合カタログ 2015

薬物分析法の開発

橡マニュアルv4c.PDF

h1_4.ai

Waters Sigma-Aldrich 1.0 mg/ml LC Waters Alliance HPLC ACQUITY UPLC H-Class Bio 30 cm Alliance HPLC UV ACQUITY UPLC TUV mm nm XBridge Protein B

VOL. 25 NO. 6 CHEMOTHERAPY 1667

Agilent

JAJP.qxp

Microsoft PowerPoint - TCI Dual ppt

A4冊子1P-P20.ai

HPLC 1M KH 2 PO 4 ph ml Anthranilic acid: AnA 600 ml ml AnA 1.0 ml / min Anthranilic acid= PRESSURE 140 kgf / cm 2

内容 1. セミ分取 HPLC システム 応用例 留意点 2. 超臨界流体クロマトグラフィー (SFC) を使用した分取の紹介

C18 カラムのエンドキャッピングは ここまで進化した! 耐久性を実現する 技術とその性能 クロマニックテクノロジーズ塚本友康小島瞬長江徳和

Mastro -リン酸基含有化合物分析に対する新規高耐圧ステンレスフリーカラムの有用性について-

JAJP.qxp

Adenosine Triphosphate Adenosine Monophosphate min min Fig.2 Chromatograms of Nucleotides Peak

Ⅱ6.3界面活性剤

3 1 2

LC ACQUITY UPLC H-Class Bio TUV Sigma, mg/ml 0.01 N 276 nm μl 0.4 ml/min L g/l / 99% / 65/15/20 v/v/v 10% 10% 0.01 N ACQUITY

中面 2 Hot News Vol 可能性 拡がる Nexera コアシェル リンク 3.6μmのコアシェルを用いれば アセトニトリル 水系で背圧10MPa 程度でご使用頂けます 1.7μm 2.6μm 3.6μm UFLC Prominence メソッド移管性

a b Chroma Graphein Chromatography

untitled

Figure 1 Detection process of ELSD. All droplets enter the evaporation process Figure 2 Only small droplets enter the evaporation process Nebulization

GPC/SEC

untitled

JAJP.qxp

平成26年度 化学物質分析法開発報告書

Group A (2,5-Dimethoxyphenyl type) 25D-NBMe (1) 25B-NBMe (2) 25I-NBMe (3) 25C-NBF () 25B-NBF (5) Group B (Benzofuran-2-yl type) Group C (-Alkoxy-3,5-d

Microsoft PowerPoint - HILICandSAC

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)

Adenosine Triphosphate Adenosine Monophosphate min Fig.2 Chromatograms of Nucleotides min Peak

Effect of Roasting on the Formation of Chlorogenic Acid Lactones in Coffee

NewsLetter-No2

日歯雑誌(H22・7月号)HP用/p06‐16 クリニカル① 田崎

Preparative chromatography

東京都健康安全研究センター研究年報

low_ JAJP.qxd

平成26年度 化学物質分析法開発報告書

LC/TOF-MS MS ( )

平成26年度 化学物質分析法開発報告書

JAJP.qxd

大和会だよりvol71


(DHA) µg/ml 2,3 4 DHA AOAC DHA C UVDHA 22 nm ph nm 5 AOAC UV UV HPLC Milli Q (Millipore Elix 1 ) Lab-Scan ( ) Fluka () o-

mastro_nakamen三校.ai

[PDF] マニュアル AKTAexplorer UNICORN ver. 4.0

pera1会社概要n

<4D F736F F D C6E30385F A B B83932E444F43>

創薬と結晶構造解析-3.key

untitled


0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2

C18①s

Chart 1.Method for Preparation of 1.25% Indomethacin Inhalation Solution (ph 7.4)


1 WSV SIR m/z Analyte RT (Min) SIR m/z Cone voltage (V) Ascorbic Acid (C) Thiamine (B1) Nicotinic Acid (B3) Pyridoxal (

Oxidative Dimerization of Tocopherols in Saturated and Unsaturated Triglycerides. III Formation of 5-(ƒÂ-Tocopheroxy)-ƒÂ-5-tocopherol and 5-(ƒÂ-Tocoph

2 Agilent OpenLAB CDS OpenLAB CDS OpenLAB CDS OpenLAB IT 2

Microsoft PowerPoint - MonoTowerカタログ_ 最終.ppt [互換モード]

UPC 2 Baiba Cabovska, Michael D. Jones, and Andrew Aubin Waters Corporation, Milford, MA, USA UPC 2 ACQUITY UPC 2TM ACQUITY SQD Empower 3 UPC GC

ESL ()-methyl 3-{4-[2-hydroxy-3-(isopropylamino)pro poxy]phenyl} propanoate monohydrochloride H 3 C O O JAN( ) JAN( )esmolol hydrochloride r-inn( )esm

JAJP.indd

JAJP

1 No.236 HP TAXUS

島津ジーエルシー総合カタログ2017【HPLCカラム】

PowerPoint プレゼンテーション

スライド 1

まえがき

Liner natomy ライナーの手引き Innovative Chromatography Products

島津ジーエルシー総合カタログ2017【HPLCカラム】

248 Nippon Shokuhin Kagaku Kogaku Kaishi Vol. /-, No./,,.2,/. (,**0) 12 * * * Microencapsulation of Glutamine with Zein by a Solvent Evaporation Metho

研修コーナー

gc-guide

Agilent BioHPLC HPLC/UHPLC /

1. 52

扉 序文 目次DVD用 .indd

すぐできる冬の省エネ・節電ガイド



”Žfi¶‰s‚ÒŒh”~”ŒŠá‘WŁ\”ƒ

パーキンソン病治療ガイドライン2002

untitled

平成23年度電気設備技術基準関係規格等調査役務請負報告書

外因性内分泌攪乱化学物質調査暫定マニュアル(水質、底質、水生生物)

パワープロジェクター WUX10 使用説明書

MAbPac RPカラム

平成25年度 化学物質分析法開発報告書

ヒト血漿中オキシステロールの高感度分析法

逆相 HPLC 分析におけるメソッド開発 1. 逆相 HPLC 分析におけるメソッド開発 1.1 カラム 1.2 移動相 1.3 試料 2. トラブルシューティング 1

Transcription:

Ultron ES-VM : HPLC HPLC 28,000, 1-120Å 5-µm Ultron ES-VM [1-] Ultron ES-VM HPLC ph pi 3.8 4.3 Ultron ES-VM ph pi ph pka = 4.4 ph 3.0 6.0 pka = 4.0 9.2 k' 1 αph 1 Ibuprofen H3 C CHCH 2 CH CH H 3 C Chlorpheniramine pka = 4.4 H3 C H 3 C CHCH 2 CH C _ Cl + H C H + CH 2 CH 2 H pka = 4.0 Cl C H + CH 2 CH 2 H pka = 9.2 Cl C H CH 2 CH 2 Hexobarbital _ H 3 C H pka = 8.2 H 3 C 1.

20 mm 0/5 ph 3.0 6.0 k' 1 α= k' 2/k' 1 2 3 ph 3.0 ph 4.0 4.6pH 5.5 2 ph 3.0 6.0 k' 1 2 phk' 1 ph 3.0 phpi 3α ph α ph 2 α 60 50 40 k 30 20 Enantiomeric samples Ibuprofen Chlorpheniramine Hexobarbital ph 2 ph 0 2 3 4 5 ph 6 7 3 2. : Column: Ultron Ultron ES-VM ES-VM : Column size: 6.0 150 mm 150 mm : Mobile phase: 20 mm 20 mm KH 2P KH 4 2 (ph P 4 4.6)/C (ph 4.6)/C 2H 5H 2 H(0/20 5 H (0/20 v/v) v/v) : Pressure: 25 ºC1 kg/cm 2 : Temperature: UV-220 25 C nm ph k' 2 ph 4.0 4.6 k' 1pKa 4.4 ph ph 5.0 6.0 k' 1 ph 5.0 6.0 k' 1 ph 3.0 k' 1 ph 3. α 2 1 0 2 3 4 5 ph Enantiomeric samples Ibuprofen Chlorpheniramine Hexobarbital 6 7 : Column: Ultron Ultron ES-VM ES-VM : Column size: 6.0 150 mm 150 mm : Mobile phase: 20 mm 20 mm KH 2P KH 4 2 (ph P 4 4.6)/C (ph 4.6)/C 2H 5H 2 H(0/20 5 H (0/20 v/v) v/v) : Pressure: 25 ºC1 kg/cm 2 : Temperature: UV-220 25 C nm ph α 2

pka = 3.9pKa = 4.0 9.2 4 3 ph 5.55 20 70 mm / 0/ 20 70 mmk' 5 mm k' 20 mm Ultron ES-VM k' α ph 4.6 4 pka = 8.95 v/v > > > Acetonitrile Ethanol 30 20 Enantiomeric samples First 1 chlorpheniramine Second 2 chlorpheniramine First 1 ketoprofen Second 2 ketoprofen Isopropanol Methanol k 0 0 20 40 60 Phosphate (mm) buffer 80 Time (min) Time (min) Time (min) Time (min) : Column: Ultron Ultron ES-VM ES-VM : Column size: 6.0 150 mm 150 mm : Mobile phase: 20 mm (ph 20 phosphate buffer 4.6)/ (0/ (ph 5.5)/ethanol v/v) : 1.0 ml/min (0/ v/v); buffer concentration = 5,, 70 : Flow rate: 25 ºC1.0 ml/min : Pressure: UV-220 1 nm kg/cm 2 Temperature: 25 C : Column: Ultron Ultron ES-VM ES-VM : Column size: 6.0 150 mm 150 mm : Mobile phase: 20 mm (ph 20 phosphate buffer 4.6)/ (0/ (ph 4.6)/organic modifier v/v) : 1.0 ml/min (0/ v/v) : Flow rate: 25 ºC1.0 ml/min : Pressure: UV-220 1 nm kg/cm 2 Temperature: 25 C 4. 5. 3

1 5 v/v 0/5 0/ v/v 20 mm ph 4.6 k' 2 k' [5] 1. Ultron ES-VM 5 5 k 1 α k 1 α k 1 α k 1 α a 24.76 1.45 12.38 1.40 24.29 1.25 3. 1.06 a 4. 2.60 1.60 1.93 3.25 2.00 2.00 1.00 a 1.70 1.52 1.15 1.23 a 20 mmph 4.6 v/v 2. k 1 α k 1 α a 12.40 1.40 13.20 1.16 a 8.00 2.14 7.80 1.46 a 2.19 1.59 1.85 1.42 a 20 mmph 4.60/ v/v0/7 v/v b 20 mmph 5.50/ v/v0/8 v/v c 20 mmph 6.00/5 v/v0/4 v/v 4

Ultron ES-VM 20 mm ph 4.60/ v/v 5 40 3 3 k' α Rs k' α 19 ES-VM 3. a 5 C 11 C 19 C 28 C 40 C k 1 18.67 11.49 7.79 4.97 2.59 k 2 23.94 14.59 9.68 6.05 3.06 α 1.28 1.27 1.25 1.22 1.18 1 446 722 59 1224 1899 2 380 563 798 890 1282 R s 1.12 1.35 1.44 1.21 1.08 a 20 mmph 4.60/ v/v Ultron ES-VM 6 ph 4.6 20 mm /0/20 v/v18 25 α ph 4.6 20 mm / 0/ v/v 15 7 [8] 18 C 22 C 25 C t 1 = 9.65 t 1 = 8.28 t 1 = 7.29 t 2 = 19.93 t 2 = 16.35 t 2 = 14.13 Time (min) Time (min) Time (min) : Column: Ultron Ultron ES-VM ES-VM : Column size: 6.0 150 mm 150 mm : Mobile phase: 20 mm (ph 20 phosphate buffer 4.6)/ (0/20 (ph 4.6)/acetonitrile (0/20 v/v) v/v) : Pressure: 18,22,25ºC 1 kg/cm 2 : Temperature: UV-220 Varied nm 6. HPLCUltron ES-VM 4.6 150 mm Ultron ES-VM 7 0.5 µl 4.6 150 mm Ultron ES-VM 1.5 3 nmol/g 15 30 [5] 2 nmol 1 µg HPLC 1 50 µl 25 µl [4] HPLC k' k' 5

Sample loading amount 0.75 µg 1.5 µg 5 µg µg 15 µg 20 Time (min) : Ultron ES-VM : Column: 4.6 150 Ultron mm ES-VM : Column size: 20 mm 4.6 KH 150 mm 2P 4 (ph 5.5)/C 2H 5H (0/4 v/v) : Mobile phase: 1.0 ml/min 20 mm KH 2 P 4 (ph 5.5)/C 2 H 5 H (0/4 v/v) Flow rate: 1.0 ml/min : Temperature: Ambient : UV-220 nm : 5-uL Injection volume: 5-uL loop : Sample: Tolperison 7. HPLC 2 Ultron ES-VM 8 2 1.0 ml/min Plate height cm cm 0.16 0.14 0.12 0. 0.08 0.06 0.04 0.02 4.6 mm id 6.0 mm id 0.50 0.75 1.00 1.25 1.50 1.75 2.00 Mobile phase flow rate 8. Ultron ES-VM 150 mm 6

Ultron ES-VM 9 25 20 mm [5] ph 3.0α ph 3.0 4.6pH ph 4.0 ph 4.6 ph 7.0 0.02 M (ph 3.0) () ( ) ph 4.0 1) ( 50%) 2) ( ) () 1) 2) ( ) ph 4.0 ( ) () 0.02 M (ph 4.6) () ( ) ph 4.6 7.0 1) ( 50%) 2) ( ) () 1) 2) ( ) ph 4.6 7.0 ( ) () : 2- (20 mm):kh 2P 4/K 2HP 4 HCH/HCH 4 CH/Ca C 3H 4H(CH) 3KH 2P 4 7

49 43 Ultron ES-VM 4 5 4. Ultron ES-VM Rs 20 mm (ph 4.6)- (0/7.5 v/v) 2.74 20 mm (ph 4.6)- (0/25 v/v) 6.06 Bay K 8644 20 mm (ph 4.6)- (0/25 v/v) 5.92 20 mm (ph 4.6)- (0/20 v/v) 3.27 20 mm (ph 4.6)- (0/ v/v) 8.41 20 mm (ph 4.6)- (0/ v/v) 3.17 20 mm (ph 6.0)- (0/3 v/v) 3.08 20 mm (ph 5.5)- (0/ v/v) 1.26 20 mm (ph 4.6)- (0/ v/v) 6.48 20 mm (ph 5.5) 2.23 20 mm (ph 5.0)- (0/5 v/v) 2.36 20 mm (ph 5.5)- (0/3 v/v) 2.34 20 mm (ph 4.6)- (0/15 v/v) 2.85 20 mm (ph 4.6)- (0/15 v/v) 4.33 1,2-20 mm (ph 5.5) 1.74 20 mm (ph 5.5)- (0/ v/v) 2.04 20 mm (ph 5.5)- (0/5 v/v) 1.15 20 mm (ph 4.6) 1.42 20 mm (ph 3.0)- (0/30 v/v) 1.26 20 mm (ph 4.6)- (0/ v/v) 1.36 20 mm (ph 4.6) 1.73 20 mm (ph 5.5)- (0/5 v/v) 1.70 20 mm (ph 4.6)- (0/ v/v) 3.04 20 mm (ph 4.6)- (0/15 v/v) 2.15 20 mm (ph 3.0)- (0/ v/v) 1.73 20 mm (ph 3.0)- (0/ v/v) 1.37 20 mm (ph 4.6)- (0/35 v/v) 3.71 20 mm (ph 4.6) 1.40 20 mm (ph 4.6)- (0/ v/v) 1.70 20 mm (ph 5.7) 1.13 20 mm (ph 5.5)- (0/ v/v) 1.38 20 mm (ph 5.5)- (0/3 v/v) 2.04 20 mm (ph 3.0)- (0/8 v/v) 1.01 20 mm (ph 5.0)- (0/15 v/v) 1.02 20 mm (ph 4.6)- (0/25 v/v) 3.31 20 mm (ph 4.6)- (0/20 v/v) 1.32 20 mm (ph 4.6)- (0/20 v/v) 0.98 20 mm (ph 6.8)- (0/30 v/v) 1.24 20 mm (ph 5.5)- (0/30 v/v) 0.98 20 mm (ph 5.5)- (0/ v/v) 1.50 20 mm (ph 4.6)- (0/ v/v) 5.16 20 mm (ph 4.6)- (0/30 v/v) 3.69 20 mm (ph 4.6)- (0/5 v/v) 1.49 8

ph 2 7.5 3 7 Ultron ES-VM 50 20 40 50 20 Ultron ES-VM 6.0 150 mm 1. T. Miwa, T. Miyakawa, and M. Kayano, Chem. Pharm. Bull., 35 (1987) 682. 2. T. Miwa, T. Miyakawa, and M. Kayano, J. Chromatogr., 408 (1987) 316. 3. M. kamoto and H. akzawa, J. Chromatogr., 504 (1990) 445. 4. Y. Hu and D. Kupfer, Drug Metabolism and Disposition, 30 (2002) 1329. 5. K. M. Kirkland, K. L. eilson, D. A. McCombs, and J. J. DeStefano, LC-GC, (1992) 322. 6. K. Ishii, S. Wakamoto, H. akai, and T. Sata, Chromatographia, 43 (1996) 413. 7. K. M. Kirkland, K. L. eilson, and D. A. McCombs., J. Chromatogr., 545 (1991) 43. 8. Y. Hu and D. Kupfer, Drug Metabolism and Disposition, 30 (2002) 1329. 9. J. Haginaka, J. Wakai, K. Takahashi, H. Yasuda, and T. Takagi, Chromatographia, 29 (1990) 587.. P. Bonato, R. Bortocan, C. Gaitani, F. Paias, M. Ina, and R. Lima, J. Braz. Chem. Soc., 13 (2), 2002. www.agilent.com/chem/jp S CH2 CH 20 Time (min) : Column: Ultron Ultron ES-VM ES-VM : Column size: 6.0 150 mm 150 mm : Mobile phase: 20 mm 20 KH mm 2P KH 4 2 (ph P 4 = (ph 4.6)/C = 4.6)/C 2H 5H 2 H= 5 H 0/20 = 0/20 v/v v/v : Pressure: 25 ºC1 kg/cm 2 : Temperature: UV-220 25 nm C. 9

Antiinflammatory Fenoprofen calcium _ C CH Ca 3+ 2H 2 () Cholinergic blocking (parasympatholytic) drugs Mepenzolate bromide C C Br _ Antiinflammatory Pranoprofen CH CH H + H 3 C 20 30 40 Time (min) Column: Ultron ES-VM : Ultron ES-VM Column size: 6.0 150 mm : 6.0 150 mm Mobile phase: 20 mm KH 2 P 4 (ph 5.6)/ : 20 mm KH C 2 H 5 H 2P (0/ 4 (ph 5.6)/ v/v) C Flow rate: 2H 5H (0/ v/v) 1.0 ml/min : 1.0 ml/min Temperature: 27 C : Detection: 27 ºC UV-220 nm (0.04 AUFS) : UV-220 nm (0.04 AUFS) 50 20 30 Time (min) : Column: Ultron Ultron ES-VM ES-VM : Column size: 4.6 150 mm 150 mm : Mobile phase: 20 mm 20 mm KH 2P KH 42 P (ph 4 (ph = 4.6) = 4.6) : Temperature: 27 ºC27 C : Detection: UV-220 UV-220 nm (0.04 nm (0.04 AUFS) AUFS) 20 30 Time (min) Column: Ultron ES-VM : Column size: Ultron 4.6 ES-VM 150 mm : Mobile phase: 4.6 150 20 mm mm KH 2 P 4 (ph 6.0)/ : 20 mm C 2 H KH 5 H 2P (0/5 4 (ph 6.0)/ v/v) Flow rate: C 2H 5H 1.0 (0/5 ml/min v/v) : Temperature: 1.0 ml/min 27 C : Detection: 27 ºC UV-220 nm (0.04 AUFS) : UV-220 nm (0.04 AUFS) Antihistamines Promethazine hydrochloride Local Anesthetic Bupivacaine Antiparkinson drugs Trihexyphenidyl S CH 2 CH 2 C H HCI CH 2 CH HCI H C (CH 2 ) 3 20 Time (min) : Column: Ultron Ultron ES-VM ES-VM : Column size: 4.6 150 mm 150 mm : Mobile phase: 20 mm 20 mm KH 2P KH 42 (ph P 4 4.6)/ (ph 4.6)/ C 2H 5H C 2 H 5 (0/20 H (0/20 v/v) v/v) : Temperature: Ambient : Detection: UV-220 UV-220 nm (0.04 nm (0.04 AUFS) AUFS) 20 Time (min) Column: : Ultron Ultron ES-VM ES-VM Column : size: 4.6 150 mm 150 mm Mobile : phase: 20 mm 20 mm KH 2P KH 42 P (ph 4 (ph 5.5)/ 5.5)/ C C (0/ (0/ v/v) v/v) Flow : rate: 1.0 ml/min 1.0 ml/min Temperature: : 25 ºC25 C Detection: : UV-220 UV-220 nm (0.04 nm (0.04 AUFS) AUFS) 5 Time (min) : Column: Ultron Ultron ES-VM ES-VM : Column size: 4.6 150 mm 150 mm : Mobile phase: 20 mm 20 KH mm 2P KH 4 2 (ph P 4 4.6)/ (ph 4.6)/ C 2H 5H C 2 H(0/ 5 H (0/ v/v) v/v) : Temperature: Ambient : Detection: UV-220 UV-220 nm (0.04 nm (0.04 AUFS) AUFS)

Antipsychotics Thioridazine hydrochloride Diuretic drugs Ethiazide Skeletal muscle relaxants Eperisone hydrochloride S S CH 2 CH 2 H 2 Cl S H S H C2H 5 C H H 3 CH 2 C C CH CH 2 HCl HCI 20 30 40 Time (min) : Column: Ultron Ultron ES-VM ES-VM : Column size: 4.6 150 mm 150 mm : Mobile phase: 20 mm 20 KH mm 2PKH 4 (ph 2 P5.5)/ 4 (ph 5.5)/ C CH(0/30 3 C (0/30 v/v) v/v) : Temperature: 31 ºC 31 C : Detection: UV-254 UV-254 nm (0.04 nm AUFS) (0.04 AUFS) 20 Time (min) : Column: Ultron Ultron ES-VM ES-VM : Column size: 4.6 150 mm 150 mm : Mobile phase: 20 mm 20 KH mm 2PKH 4 (ph 2 P 4.6) 4 (ph 4.6) : Temperature: 25 ºC25 C : Detection: UV-220 UV-220 nm (0.04 nm (0.04 AUFS) AUFS) 20 Time (min) : Column: Ultron Ultron ES-VM ES-VM : Column size: 4.6 150 mm 150 mm : Mobile phase: 20 mm 20 KH mm 2P KH 4 (ph 2 P5.5)/ 4 (ph 5.5)/ C 2H 5H C 2 H(0/5 5 H (0/5 v/v) v/v) : Temperature: 25 ºC 25 C : Detection: UV-220 UV-220 nm (0.04 nm AUFS) (0.04 AUFS) 1,2-1,2-Diphenylethylamine Prenylamine lactate 2-2-Phenyl propionic acid CH (CH 2 ) 2 H CH CH 2 H 3 C CH CH CH 2 CH H 2 20 30 40 Time (min) 20 30 Time (min) Column: Ultron ES-VM Column : size: Ultron 4.6 ES-VM 150 mm Mobile : phase: 4.6 150 20 mm mm KH 2 P 4 (ph 5.5) Flow : rate: 20 mm 1.0 ml/min KH 2P 4 (ph 5.5) Temperature: : 1.0 ml/min 25 C Detection: : 25 ºC UV-220 nm (0.04 AUFS) : UV-220 nm (0.04 AUFS) Column: Ultron ES-VM Column size: 4.6 150 mm : Ultron ES-VM Mobile phase: 20 mm KH 2 P 4 (ph 5.0)/ : 4.6 150 mm C (0/15 v/v) : 20 mm KH 2P 4 (ph 5.0)/ Flow rate: 1.0 ml/min C (0/15 v/v) Temperature: 25 C : 1.0 ml/min (0.04 AUFS) : 25 ºC : UV-220 nm (0.04 AUFS) 20 Time (min) : Column: Ultron ES-VM Ultron ES-VM : Column size: 4.6 150 4.6 mm 150 mm : Mobile phase: 20 mm 20 mm KH 2 P 4 (ph 4.6) KH2P4 (ph 4.6) : Temperature: 25 ºC 25 C : Detection: UV-220 UV-220 nm (0.04 nm AUFS) (0.04 AUFS) 11

() rnidazol (Antibiotic) a 2 P a 20.208 23.128 () Bicalutamide (Antiandrogen) CF 3 H 3 C F S 2 CH 2 C C C H H 8.060 15.200 aftopidil (Alpha1a-adrenergic (α1a-) receptor antagonist) H CH 2 CHCH 2 H 3 C 7.404.193 0 20 30 Minute Column: Ultron ES-VM (5 µm) : Ultron ES-VM (5 µm) Column size: 4.6 150 mm : 4.6 150 mm Mobile phase: 20 mm KH 2 P 4 (ph 3.0)/ : 20 mm KH C 2P (88/12 4 (ph 3.0)/ v/v) CH Flow rate: 3C (88/12 v/v) 1.0 ml/min : 1.0 ml/min Temperature: 25 C : 25 ºC Sample: : UV-220 rnidazol nm disodium phosphate : 0.2 mg/ml Injection vol: 0.2 mg/ml 3 µl : 3 µl 0 5 15 20 25 Minute : Column: Ultron Ultron ES-VM ES-VM (5 µm) (5 µm) : Column size: 4.6 150 mm 150 mm : Mobile phase: 20 mm 20 mm KH 2P KH 42 (ph P 4 4.6)/ (ph 4.6)/ C (88/12 C (88/12 v/v) v/v) : Temperature: 25 ºC25 C : Detection: UV-220 UV-220 nm nm : Sample: CH Bicalutamide in 33C 0.1 mg/ml 0.1 mg/ml : Injection vol: 3 µl3 µl 0 5 15 Minute Column: : Ultron Ultron ES-VM ES-VM (5 µm) (5 µm) Column : size: 4.6 150 150 mm mm Mobile : phase: 20 mm 20 mm KH 2P KH 42 P (ph 4 (ph 7.0)/ 7.0)/ C (75/25 C (75/25 v/v) v/v) Flow : rate: 1.0 ml/min 1.0 ml/min Temperature: : 25 ºC 25 C Detection: : UV-220 UV-220 nm nm Sample: : 0.5 aftopidil mg/ml Injection : vol: 1 µl1 µl 20 Cetirizine hydrochloride ( ) (Antihistamine) Cl CH CH 2 CH 2 CH 2 CH 2HCI.700 12.595 Fulvastatin sodium (HMG-CoA ) (HMG-CoA reductase inhibitor) H Ca F 34.546 39.913 Amlodipine besilate (Calcium channel blocker) ( ) H CH 2 CH 2 CH 2 H 2 C CC 2 H 5 6.783 11.331 Cl. S 3 H 0 5 15 Minute Column: Ultron ES-VM (5 µm) : Column size: Ultron 4.6 ES-VM 150 mm (5 µm) : Mobile phase: 4.6 150 20 mm mmkh 2 P 4 (ph 4.6)/ : 20 mm CHKH 3 C 2P (90/ 4 (ph 4.6) v/v) Flow rate: /C 1.0 ml/min (90/ v/v) : Temperature: 1.0 ml/min 25 C : Detection: 25 ºCUV-235 nm : Sample: : UV-235 Cetirizine nm hydrochloride 0.2 mg/ml mg/ml : Injection vol: 2 µl 2 µl 20 0 20 30 40 50 60 Minute Column: : Ultron Ultron ES-VM ES-VM (5 µm) (5 µm) Column : size: 4.6 150 150 mm mm Mobile : phase: 20 mm 20 mm KH 2P KH 4 2 P (ph 4 (ph 3.0)/ 3.0)/ C C (88/12 (88/12 v/v) v/v) Flow : rate: 1.0 1.0 ml/min ml/min Temperature: : 25 ºC 25 C Detection: : UV-235 UV-235 nm nm Sample: : Fulvastatin sodium 0.5 mg/ml 0.5 (Solvent: mg/ml ( : ) methanol) Injection : vol: 1 µl1 µl 0 5 15 20 Minute Column: : Ultron Ultron ES-VM ES-VM (5 µm) (5 µm) Column : size: 4.6 150 150 mm mm Mobile : phase: mm mm a 2HP a 2 HP 4 (ph 4 (ph 7.0)/ 7.0)/ C CH (78/22 3 C (78/22 v/v) v/v) Flow : rate: 1.0 ml/min 1.0 ml/min Temperature: : 25 ºC 25 C Detection: : UV-237 UV-237 nm nm Sample: : 0.02 Amlodipine besilate mg/ml ( : ) 0.02 mg/ml (Solvent: Methanol) Injection : vol: 2 µl2 µl 12

Fexofenadine hydrochloride ( ) (Antihistaminic) Sodium rabeprazole ( ) (Proton pump inhibitor) H H C (CH 2 ) 3 CH C CH HCl H 2 CH 2 CH 2 CH 3 C CH 2 S a 7.313 8.718 22.587 27.812 0 4 8 12 16 : Column: Ultron Ultron ES-VM ES-VM (5 µm) (5 µm) : Column size: 4.6 150 mm 150 mm : Mobile phase: 20 mm 20 KH mm 2P KH 4 (ph 2 P4.6)/ 4 (ph 4.6)/ C CH(95/5 3 C (95/5 v/v) v/v) : Temperature: 25 ºC25 C : Detection: UV-220 UV-220 nm nm : Sample: Fexofenadine hydrochloride 0.3 mg/ml 0.3 mg/ml : Injection vol: 1 µl 1 µl 0 20 30 40 Minute : Column: Ultron Ultron ES-VM ES-VM (5 µm) (5 µm) : Column size: 4.6 150 mm 150 mm : Mobile phase: 20 mm 20 KH mm 2P KH 4 (ph 2 P6.0)/ 4 (ph 6.0)/ C CH(95/5 3 C (95/5 v/v) v/v) : Temperature: 25 ºC25 C : Detection: UV-225 UV-225 nm nm : Sample: Sodium rabeprazole 0.2 mg/ml 0.2 mg/ml : Injection vol: 3 µl 3 µl 13

www.agilent.com/chem/jp Agilent Technologies, Inc. 2008 Printed in Japan July 11, 2008 5989-8748JAJP